Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin - CKD Bio Corporation

Next Previous
Drug Profile

Botulinum toxin - CKD Bio Corporation

Alternative Names: CKDB-501; CKDB-501A; CKDB-501B; CU-20101

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CKD Pharmaceuticals
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines
  • Phase I Muscle spasticity

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Glabellar-lines in South Korea (IM, Powder)
  • 11 Jun 2024 Phase-III clinical trials in Glabellar lines in China (Parenteral) (NCT06585696) (CTR20241540)
  • 26 Mar 2024 Healis Therapeutics entered into a R&D agrrement with Massachusetts General Hospital and affiliates of Harvard Medical School for clinical development of Botulinum toxin for Psychiatric disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top